Vernalis Gives Partnering a Second Chance

Vernalis has bought back rights to its Frova migraine treatment in North America from Elan, agreeing to pay $55 million over the next two years. Frova, sold there by Elan and UCB, had failed to reach even the most modest sales expectations. Now Vernalis plans to re-partner the drug, hoping a label-extension to menstrual-associated migraine lands it significantly better terms than its original 1998 deal with Elan. But Vernalis needs to raise money to complete the buyout, and the dynamics of the US migraine market suggest that until it can differentiate the drug on the basis of the MAM label, a huge primary care sales force would be necessary to gain a respectable share of the market.

When Pfizer Inc. launched the seventh triptan migraine therapy into the US market in February 2003, it did so with a bang. The Big Pharma rolled out eletriptan (Relpax) under the considerable steam of 6,000 sales reps, aiming to take a bite out of market-dominating sumatriptan (Imitrex) from GlaxoSmithKline PLC . Barely noticed was the flagging progress of the sixth entrant, frovatriptan (Frova), launched in late 2002 and sold by Elan Corp. PLC , which focused on neurologists, and UCB Pharma SA , the US affiliate of Belgian conglomerate UCB Group 's UCB SA , which details primary care physicians (PCPs). [See Deal](See Exhibit 1.)

While Elan had managed to capture a respectable 7% market share among neurologists, these doctors write only 1% of total...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.